8-K: CytoSorbents Highlights Sepsis Efficacy Amid Regulatory Setbacks

CytoSorbents Corporation highlights new studies demonstrating the vital and evolving role of its CytoSorb therapy in treating sepsis and septic shock, while facing regulatory denials for its DrugSorb-ATR device.

Summary

• CytoSorbents issued a press release on July 31, 2025, highlighting new studies on CytoSorb therapy for sepsis and septic shock.
• The company plans to host a World Sepsis Day Global Webinar on September 10, 2025, to discuss CytoSorb therapy best practices.
• CytoSorb therapy is designed to supplement traditional antibiotic therapy by addressing severe inflammation, shock, capillary leak, fluid overload, and organ failure in sepsis.
• Sepsis and septic shock afflict an estimated 49 million people worldwide annually, causing 11 million deaths, accounting for up to 20% of all global deaths.
• Standard treatments for septic shock often result in mortality rates of 30-50%.
• CytoSorb is approved in the European Union and distributed in over 70 countries globally, with nearly 300,000 human treatments cumulatively.
• A 100-patient U.S. COVID-19 registry study (Critical Care, 2023) reported 74% 90-day survival (82% with early treatment) in critically ill patients with refractory respiratory failure and sepsis, outperforming U.S. benchmarks of approximately 50%.
• A retrospective study of 175 septic shock patients (Journal of Intensive Care Medicine, 2025) demonstrated that early and intensive CytoSorb use (3 cartridges within 2-3 days) nearly doubled survival rates (70% observed vs. 37% predicted).
• A meta-analysis of 744 septic shock patients (Journal of Clinical Medicine, 2025) showed statistically significant improvements in hemodynamics, vasopressor requirements, and survival, including reduced in-hospital mortality (OR 0.64 [0.42-0.97], p=0.036, n=462) and halved 28-30 day mortality (OR 0.46 [0.28-0.78], p=0.003, n=250).
• The international COSMOS registry (Journal of Intensive Medicine, 2025) highlighted improved mortality, oxygenation, shock reversal, fluid balance, and lactate levels in patients, 58% of whom had septic shock.
• The U.S. FDA issued a De Novo Denial Letter for DrugSorb-ATR on April 25, 2025, identifying remaining deficiencies.
• The company plans to appeal the FDA decision, with an appeal hearing confirmed for June 27, 2025, and expected completion by the end of August 2025.
• Health Canada issued a Notice of Refusal for the Medical Device License application for DrugSorb-ATR on June 26, 2025, also identifying remaining deficiencies.
• The company plans to file a Level 1 Request for Reconsideration with Health Canada after the U.S. FDA review.

Sentiment

Score: 4

Explanation: While the clinical data for CytoSorb in sepsis treatment is highly positive and reinforces its efficacy, the significant regulatory setbacks for DrugSorb-ATR in both the U.S. and Canada introduce considerable uncertainty and delay for a key product in development. The company's confidence in resolving these issues through appeals is noted, but the denials themselves are a negative development.

Positives

• CytoSorb therapy demonstrates improved clinical outcomes for sepsis and septic shock patients, supported by recent studies.
• Strong safety record and numerous peer-reviewed publications back CytoSorb's efficacy in various clinical applications.
• U.S. COVID-19 registry data showed 74% 90-day survival (82% with early treatment) using CytoSorb and ECMO, significantly outperforming benchmarks of approximately 50%.
• Early and intensive CytoSorb use nearly doubled survival rates (70% observed vs. 37% predicted) in a 175-patient septic shock study.
• A meta-analysis showed statistically significant improvements in hemodynamics, vasopressor requirements, and survival, including reduced in-hospital mortality (OR 0.64) and halved 28-30 day mortality (OR 0.46).
• CytoSorb is approved in the EU and distributed in over 70 countries, with nearly 300,000 cumulative treatments.
• CytoSorb has FDA Emergency Use Authorization for critically ill COVID-19 patients in the U.S.
• DrugSorb-ATR received two FDA Breakthrough Device Designations.

Negatives

• The U.S. FDA issued a De Novo Denial Letter for DrugSorb-ATR on April 25, 2025, citing remaining deficiencies.
• Health Canada issued a Notice of Refusal for DrugSorb-ATR's Medical Device License application on June 26, 2025, citing remaining deficiencies.
• The complexity of sepsis has historically led to the failure of hundreds of therapy candidates and over 100 Phase II and III clinical trials over many decades.

Risks

• Inability to resolve remaining deficiencies in the FDA denial letter and the Health Canada Notice of Refusal for DrugSorb-ATR.
• Failure to successfully appeal the FDA's and Health Canada's decisions regarding DrugSorb-ATR.
• Risks discussed in the Annual Report on Form 10-K filed on March 31, 2025, and Quarterly Reports on Form 10-Q.
• Potential impact of restructuring of the direct sales team and strategy in Germany.

Future Outlook

The company expects the FDA supervisory review process for DrugSorb-ATR to be completed by the end of August 2025, with a final regulatory decision anticipated in 2025. The company also plans to file a Level 1 Request for Reconsideration with Health Canada for DrugSorb-ATR after the U.S. FDA review is completed.

Management Comments

• "For more than a decade, CytoSorbents has partnered with clinicians and scientists to improve the treatment of sepsis and septic shock by supplementing traditional antibiotic therapy with the powerful, broad-spectrum blood purification capability of CytoSorb." Dr. Phillip Chan, CEO.
• "While antibiotics target the source of infection, CytoSorb addresses the other major drivers of septic shock, including severe inflammation, shock, capillary leak, fluid overload, and organ failure." Dr. Phillip Chan, CEO.
• "Recent studies reinforce that, like antibiotics, CytoSorb therapy is most effective when initiated early, applied intensively, and continued for an appropriate duration." Dr. Phillip Chan, CEO.
• "Septic shock remains one of the most devastating and complex challenges in critical care. Despite decades of research, outcomes remain poor with limited treatment options. CytoSorb, guided by the experience and insight of clinicians and scientists around the world, is helping that change that." Dr. Phillip Chan, CEO.
• "With an ever-expanding body of published clinical evidence including hundreds of peer-reviewed studies such as those mentioned above, real-world data, and impactful success stories, CytoSorb continues to evolve as a powerful therapy to treat critical illnesses such as septic shock, particularly when used early, intensively, and of the right duration just like antibiotics." Dr. Phillip Chan, CEO.
• "In treating the sickest patients in the hospital, we are proud of our mission of working to save lives—together." Dr. Phillip Chan, CEO.
• "The Company believes these items can be most effectively and expeditiously resolved through the formal appeals process, which facilitates engagement with FDA senior leadership and our external surgical experts."
• "The Company continues to believe that remaining deficiencies in its De Novo application can be effectively resolved through this supervisory review process which is expected to be completed by the end of August 2025, and that a final regulatory decision can be achieved in 2025."

Industry Context

Sepsis and septic shock are critical, life-threatening conditions affecting millions globally with high mortality rates, despite decades of research and numerous failed therapy candidates. CytoSorbents positions CytoSorb as a broad-spectrum solution that addresses multiple drivers of septic shock, differentiating it from single-target approaches that have historically failed to show consistent benefit in this complex medical challenge.

Comparison to Industry Standards

• A 100-patient U.S. COVID-19 registry study showed 74% 90-day survival (82% with early treatment) using CytoSorb and ECMO, significantly outperforming published U.S. survival benchmarks of approximately 50% when CytoSorb was not used.
• A retrospective study of 175 septic shock patients demonstrated that early and intensive CytoSorb use nearly doubled survival rates (70% observed vs. 37% predicted), indicating superior outcomes compared to predicted rates.
• A meta-analysis of 744 septic shock patients compared 449 patients treated with CytoSorb and standard of care versus 295 control patients receiving standard of care alone, demonstrating statistically significant improvements in hemodynamics, vasopressor requirements, and survival with CytoSorb.
• CytoSorb's comprehensive, multi-faceted approach to sepsis and septic shock is highlighted as a differentiator from other approaches that often focus on a single target or pathway, which have historically failed to show consistent benefit in the industry.

Stakeholder Impact

• Shareholders: Potential positive impact from strong CytoSorb clinical data, but negative impact from regulatory delays and uncertainty for DrugSorb-ATR.
• Patients: Continued access to CytoSorb therapy for sepsis and septic shock, with potential for improved outcomes. Delayed access to DrugSorb-ATR in the U.S. and Canada.
• Clinicians: Continued support and education on CytoSorb best practices.

Next Steps

• Host a World Sepsis Day Global Webinar on September 10, 2025.
• Complete the FDA supervisory review process for DrugSorb-ATR by the end of August 2025.
• Achieve a final regulatory decision for DrugSorb-ATR in the U.S. in 2025.
• File a Level 1 Request for Reconsideration with Health Canada for DrugSorb-ATR after the U.S. FDA review.
• Continue to delve into sepsis treatment details via the company's new septic shock blog series.
• Continue to share first-hand experiences with CytoSorb via the "Voices Around the World" segment.

Key Dates

Recommendation

The strong clinical data for CytoSorb in treating sepsis and septic shock is a significant positive, demonstrating the product's efficacy and market potential in critical care. However, the simultaneous regulatory denials for DrugSorb-ATR in both the U.S. and Canada introduce substantial uncertainty and delays for a product that has received Breakthrough Device Designations. While management expresses confidence in resolving these issues through appeals, the path to commercialization for DrugSorb-ATR is now prolonged and uncertain. Given the mixed news, with strong performance of an existing product offset by significant regulatory hurdles for a future growth driver, a "hold" recommendation is appropriate. Investors should monitor the outcome of the regulatory appeals closely before making further investment decisions.

Keywords

Sepsis, Septic Shock, CytoSorb, Blood Purification, Critical Care, Medical Device, FDA, Health Canada, DrugSorb-ATR, Extracorporeal, Inflammation, Organ Failure, NASDAQ: CTSO